Bariatric surgery versus conventional therapy in obese Korea patients: a multicenter retrospective cohort study

Yoon-Seok Heo1,10, Joong-Min Park2, Yong-Jin Kim3, Seong-Min Kim4, Do-Joong Park5, Sang-Kuon Lee6, Sang-Moon Han7, Kyung-Won Shim8, Yeon-Ji Lee9, Ja-Youn Lee10, Jin-Won Kwon10,11

1Department of Surgery, Inha University College of Medicine, Incheon, 2Department of Surgery, Chung-Ang University College of Medicine, Seoul, 3Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, 4Department of Surgery, Gachon University of Medicine and Science, Incheon, 5Department of Surgery, Seoul National University Bundang Hospital, Seongnam, 6Department of Surgery, The Catholic University of Korea College of Medicine, Seoul, 7Department of Surgery, Kangnam CHA Hospital, Seoul, 8Department of Family Medicine, Ewha Womans University School of Medicine, Seoul, 9Department of Family Medicine, Inha University College of Medicine, Incheon, 10National Evidence-based Healthcare Collaborating Agency, Seoul, 11Kyungpook National University College of Pharmacy, Daegu, Korea

Purpose: In Korea, the results of bariatric surgery have not been compared with those of nonsurgical treatment. The purpose of this study was to evaluate the effectiveness and safety of bariatric surgery vs. conventional nonsurgical treatment in severely obese Koreans. Methods: In this retrospective cohort study, we reviewed the medical charts of 261 consecutive subjects who underwent bariatric surgery and 224 subjects who were treated with weight control medication and lifestyle modification therapy between January 2008 and February 2011. Measures of clinical effectiveness, including change in weight (%) and comorbid diseases, and occurrence of complications, were investigated for 18 months after bariatric surgery. Results: Body mass index (BMI) was higher in the surgery group than in the conventionally treated group (mean ± standard deviation, 39.0 ± 6.2 vs. 34.3 ± 3.8). Diabetes was more prevalent in the surgery group than in the conventionally treated group (39.1% vs. 12.9%). The change in weight (%) between baseline and 18 months posttreatment was significantly greater in the surgery group (22.6%) than in the conventional therapy group (6.7%). While 57%, 47%, and 84% of subjects recovered from diabetes, hypertension, and dyslipidemia, respectively, in the surgery group, 10%, 20%, and 24% of subjects recovered from these conditions in the conventional group. Fifty-one subjects (19.5%) in the surgery group reported 61 complications (23.4%). Conclusion: Bariatric surgery in Korea was significantly more effective than conventional treatment for weight loss and recovery from comorbidities such as diabetes, hypertension, and dyslipidemia, with a reasonable complication rate.

Keywords: Bariatric surgery, Korea, Morbid obesity, Cohort
INTRODUCTION

Obesity is an epidemic healthcare problem worldwide. In the United States, the prevalence of obesity, defined as a body mass index (BMI) \( \geq 30 \text{ kg/m}^2 \), has increased, and now includes \( > 30\% \) of the population [1]. Data from the Korean National Health and Nutritional Examination Survey indicate that the prevalence of obesity in Korea, defined as a BMI \( > 25 \text{ kg/m}^2 \), increased from 26% in 1998 to 31% in 2009 [2]. During the same period, the prevalence of severe obesity (BMI \( > 30 \text{ kg/m}^2 \)) increased markedly from 2.4 to 4.7%. Although the prevalence of obesity in Korea has been increasing rapidly, it remains much lower than in Western countries. However, Asians are more predisposed to abdominal obesity than are Western individuals, and obesity comorbidities such as diabetes, high blood pressure, high plasma triglyceride (TG) level, and low high-density lipoprotein cholesterol level seem to occur at a BMI that is much lower than the World Health Organization recommended cutoff value for obesity in Asians [3]. Therefore, different criteria for obesity are applied depending on ethnicity and nationality. Whereas severe obesity is defined as a BMI \( \geq 35 \text{ kg/m}^2 \) in Western populations, the cutoff value for severe obesity has been lowered to a BMI \( \geq 30 \text{ kg/m}^2 \) in Asians [4-6].

In Western society, bariatric surgery is recommended for individuals with a BMI \( \geq 35 \text{ kg/m}^2 \) with comorbidities or a BMI \( \geq 40 \text{ kg/m}^2 \) without comorbidities. The Asian-Pacific Bariatric Surgery Group recommends bariatric surgery for obese Asians with a BMI \( \geq 32 \text{ kg/m}^2 \) with comorbidities or a BMI \( \geq 37 \text{ kg/m}^2 \) without comorbidities [7]. A survey of Korean bariatric surgeons found that the criteria for this recommendation in Korea are slightly lower than the Asian criteria (i.e., BMI \( \geq 30 \text{ kg/m}^2 \) with comorbidities or BMI \( \geq 35 \text{ kg/m}^2 \)), which correspond to the cutoff values for severe obesity recommended by the Asian-Pacific Group.

The first bariatric surgery in Korea was performed in 2003 [8], and about 1,000 bariatric surgeries have been performed annually since 2011. Laparoscopic adjustable gastric banding (LAGB), laparoscopic Roux-en-Y gastric bypass (LRYGB), and laparoscopic sleeve gastrectomy (LSG) are the three most common bariatric procedures performed in Korea. However, the effect of bariatric surgery has not been compared with that of nonsurgical treatment in a Korean population.

Therefore, we conducted a comparative analysis of the results of bariatric surgery and conventional nonsurgical treatment in severely obese patients. The purpose of this study was to evaluate the effectiveness and safety of bariatric surgery vs. conventional nonsurgical treatment in severely obese Koreans.

METHODS

Data source and patient identification

We used a retrospective cohort design with a medical chart review to investigate the effectiveness of bariatric surgery compared with that of conventional therapy. The surgery group included adults who underwent consecutive bariatric surgeries at the Departments of Surgery of seven Korean tertiary medical centers between January 2008 and February 2011. The conventional group included adults who were treated with conventional therapies, such as weight control medication, lifestyle modification therapy, and educational program with dietician and exercise practitioner at the Departments of Family Medicine of two Korean tertiary medical centers during the same period. Patients who were \( \leq 17 \) years old and/or had a BMI \( < 30 \text{ kg/m}^2 \) were not included in this study. The ethics review board of each hospital and the National Evidence-Based Healthcare Collaborating Agency involved in this study approved the study protocol.

Data collection

Baseline height, weight, blood pressure, and laboratory data were collected by physical examination and laboratory assessments within a few days before bariatric surgery in the surgery group. These data were collected in the conventional therapy group at the first visit to start a weight loss program in the family medicine departments. Weight, blood pressure, and laboratory findings were collected over time when the subjects visited the hospital. Medical history information before bariatric surgery or the first visit for conventional therapy was investigated.
through a chart review. Descriptive information of the event, onset date, and hospitalization were collected to investigate complications related to bariatric surgery.

**Clinical effectiveness**

The clinical effectiveness of weight loss was investigated using two parameters. The first parameter was change in weight (%), calculated by dividing weight change from baseline by baseline weight. The second parameter was the percentage of excess weight loss (%EWL), calculated by dividing the weight change from baseline by excess weight, which was obtained by subtracting ideal body weight from actual baseline weight. Ideal body weight was calculated using height-adjusted weight, depending on sex, for a medium frame according to the 1983 Metropolitan Life Insurance Company tables [9].

Recovery from comorbidities such as diabetes, hypertension, and dyslipidemia was investigated over time. Diabetes was defined as the use of medication, fasting blood glucose level $\geq 126$ mg/dL, or glycosylated hemoglobin (HbA1C) concentration $\geq 6.5\%$. Hypertension was defined as the use of medication, systolic blood pressure $\geq 140$ mmHg, or diastolic blood pressure $\geq 90$ mmHg. Dyslipidemia was defined as the use of medication, total cholesterol (TC) level $\geq 240$ mg/dL, TG level $\geq 200$ mg/dL, or low-density lipoprotein cholesterol (LDL-C) level $\geq 160$ mg/dL. Patients who did not meet the criteria for a given comorbidity were considered to have recovered from that comorbidity after intervention.

**Statistical analysis**

We summarized the patient characteristics of the two groups, and compared the baseline characteristics between groups using a t-test for continuous variables and a chi-squared test for categorical variables. To investigate weight change, weight measurements obtained during routine visits were summarized at 3-month intervals. For example, if one patient’s weight was measured twice during a 3-month period from baseline, the weight value at 3 months was the mean value of the two measurements. Study outcomes such as change in weight (%) and %EWL were summarized at 0 (baseline), 3, 6, 9, 12, 15, and 18 months, and 95% confidence intervals (CIs) were calculated. The t-test was used to compare study outcomes between the two groups at each time point. Matching and the generalized estimating equation (GEE) model were used to balance confounding factors at baseline between the two groups [10]. Three matching variables were considered: age ($\pm 5$ years), BMI ($\pm 3$ kg/m$^2$), and sex. The dependent variable for the GEE model was change in weight (%), and measurement time, age, and sex were included as independent variables. Measurement time and age were input as continuous variables. Two independent researchers inputted data into the data collection forms. Then, data entry errors were checked using the SAS ver. 9.2 (SAS Institute Inc., Cary, NC, USA) and corrected. Data were analyzed using the SAS software.

**RESULTS**

**Clinical characteristics**

We identified 261 subjects in the surgery group and 224 subjects in the conventional therapy group. Patient characteristics are shown in Table 1. The median follow-up periods were 9 months for the surgery group and 8 months for the conventional therapy group. BMI was higher in the surgery group than in the conventional therapy group (mean $\pm$ standard deviation, $39.0 \pm 6.2$ vs. $34.3 \pm 3.8$ kg/m$^2$).

| Characteristic          | Surgery group (n = 261) | Conventional therapy group (n = 224) | P-value |
|-------------------------|-------------------------|-------------------------------------|---------|
| Male sex                | 64 (24.5)               | 97 (43.3)                           | $<0.001$|
| Age (yr)                | 35.75 ± 10.75           | 40.58 ± 13.32                       | $<0.001$|
| BMI (kg/m$^2$)          | 39.0 ± 6.2              | 34.3 ± 3.8                          | $<0.001$|
| 30 $\leq$ BMI $< 35$   | 74 (28.4)               | 145 (64.7)                          | $<0.001$|
| 35 $\leq$ BMI $< 40$   | 95 (36.4)               | 65 (29.0)                           | $<0.001$|
| 40 $\leq$ BMI          | 92 (35.3)               | 14 (6.3)                            | $<0.001$|
| Smoking                 | 50/241 (20.7)           | 47/166 (28.3)                       | $<0.001$|
| Alcohol consumption     | 75/241 (31.1)           | 79/166 (47.6)                       | $<0.001$|
| Unmarried               | 115/230 (50.0)          | 46/136 (33.8)                       | $<0.001$|
| History of diabetes     | 102 (39.1)              | 29 (12.9)                           | $<0.001$|
| History of hypertension | 146 (55.9)              | 119 (53.1)                          | $<0.001$|
| History of dyslipidemia | 125 (47.9)              | 112 (50.0)                          | $<0.001$|
| Follow-up period (day)  | 263 ± 204.3             | 234 ± 380.4                         | $<0.001$|

Values are presented as number (%) or mean ± SD. BMI, body mass index.
Mean age was lower in the surgery group than in the conventional therapy group (36 ± 10.8 vs. 41 ± 13.3 years). In total, 75.5% of patients in the surgery group and 56.7% of patients in the conventional therapy group were female. Diabetes was more prevalent in the surgery group than in the conventional therapy group (39.1% vs. 12.9%). In the surgery group, 27.6% of procedures were LAGB, 28.0% were LRYGB, and 44.4% were LSG. Most subjects (95%) in the conventional group used antiobesity drugs. Phentermine (26.3%) was the most frequently prescribed medicine, followed by sibutramine (24.1%), fluoxetine (12.8%), mazindol (10.5%), bupropion (10.1%), and orlistat (4.9%). Sibutramine was withdrawn from the Korean market at the end of 2010.

**Change in body weight**

Treatment outcomes such as change in weight (%) are shown in Fig. 1. The change in weight (%) from baseline to 18 months was significantly higher in the surgery group (22.6%; 95% CI, 19.1 to 26.0%) than in the conventional therapy group (6.7%; 95% CI, 4.4 to 9.1%). This pattern was consistent with %EWL. The %EWL of surgery group was 61.4% whereas the %EWL of conventional therapy group was 20.6% at 18 months after treatment. The surgery group showed significant weight loss (P < 0.001) at each time point throughout the 18-month follow-up period in the subgroup analysis in terms of BMI; 30 ≤ BMI < 35 and BMI ≥ 35 groups (Fig. 2).

There was no significant difference of change in weight (%) from baseline to 18 months according to operative procedures (20.8% for LAGB, 26.6% for LRYGB, and 22.3% for LSG).

After age, sex, and BMI were matched between the two groups, the pattern of change in weight (%) was similar to that before matching. Weight change was greater in the surgery group, with a similar significance before and after matching (P < 0.001).

Time and treatment effects for change in weight (%) from baseline using the GEE are described in Table 2. Change in weight (%) was 1.2% greater in the surgery group than in the conventional therapy group.

![Fig. 1. Comparison of treatment outcomes between surgery and conventional therapy groups.](image1)

![Fig. 2. Percentage of weight change in surgery and conventional therapy groups in subgroup analysis in terms of body mass index (BMI) (30 ≤ BMI < 35 and BMI ≥ 35).](image2)
Table 2. Results of generalized estimating equation analysis

|                          | Estimate (95% confidence interval) | P-value |
|--------------------------|----------------------------------|---------|
| Observation time (mo)    | 0.098 (0.031 – 0.165)            | 0.004   |
| Treatment method         |                                   |         |
| Surgery                  | 3.239 (2.465 – 4.013)             | < 0.001 |
| Conventional (reference) |                                   |         |
| Observation time and     | 1.226 (1.048 – 1.404)             | < 0.001 |
| treatment method         |                                   |         |
| Observation time and     |                                   |         |
| conventional (reference) |                                   |         |
| Sex                      | 0.840 (0.124 – 1.803)             | 0.088   |
| Female                   |                                   |         |
| Male (reference)         | -0.035 (-0.070 – 0.000)           | 0.051   |

Table 3. Recovery from diabetes, hypertension, and dyslipidemia in the surgery and conventional therapy groups

|                          | Surgery group (n = 261) | Conventional therapy group (n = 224) | P-value |
|--------------------------|-------------------------|-------------------------------------|---------|
| Diabetes                 |                         |                                     |         |
| Prevalence               | 102/261 (39.1)          | 29/224 (12.9)                       | < 0.001 |
| Remission                | 48/84 (57.1)            | 2/21 (9.5)                          | < 0.001 |
| Hypertension             |                         |                                     |         |
| Prevalence               | 149/261 (57.1)          | 119/224 (53.1)                      | 0.382   |
| Remission                | 40/85 (47.1)            | 17/86 (19.8)                        | < 0.001 |
| Dyslipidemia             |                         |                                     |         |
| Prevalence               | 99/261 (37.9)           | 93/224 (41.5)                       | 0.312   |
| Remission                | 52/62 (83.9)            | 23/60 (23.6)                        | < 0.001 |

Values are presented as number (%).

Table 4. Postoperative complications in the surgery group

|                          | All (n = 72) | LAGB (n = 73) | LRYGB (n = 116) | LSG (n = 116) | P-value |
|--------------------------|--------------|---------------|-----------------|---------------|---------|
| Total                     | 51 (19.5)    | 21 (29.2)     | 16 (21.9)       | 14 (12.1)     | 0.013   |
| First 30 PODs            | 26 (10.0)    | 9 (12.5)      | 9 (12.3)        | 8 (6.9)       | NS      |
| After POD30              | 32 (12.3)    | 16 (22.2)     | 9 (12.3)        | 7 (6.0)       | < 0.001 |

Values are presented as number (%).

LAGB, laparoscopic adjustable gastric banding; LRYGB, laparoscopic Roux-en-Y gastric bypass; LSG, laparoscopic sleeve gastrectomy; POD, postoperative day; NS, not significant.

In this retrospective study, we examined the records of patients who had undergone bariatric surgery to determine the effectiveness for weight reduction and improvement in comorbid diseases, as compared with that of conventional medical therapy. We showed that bariatric surgery was more effective than conventional therapy for weight loss and treatment of comorbid diseases in severely obese patients in Korea. Observed effects on weight loss were consistent after adjusting for major confounders such as BMI, age, and sex.

The effectiveness of bariatric surgery has been well established in Western countries, where the prevalence of obesity is high. Bariatric surgery is the most effective option for weight loss in severely obese patients [11-13]. However, the first bariatric surgery was performed in Korea relatively recently, in 2003. About 1,000 bariatric
surgeries were performed last year. The most frequent bariatric procedure (about 70%) was LAGB performed in private clinics. Because the history of bariatric surgery in Korea is short, few long-term investigations or comparative analyses with conventional therapy have been reported. Additionally, whether the results of bariatric surgery in Korea are comparable with those in Western countries remains unknown. This study is the first report of the results of Korean multicenter consecutive bariatric surgeries.

Our weight loss findings are in agreement with those of retrospective studies [13,14]. Many studies have reported not only the weight reduction effect, but also the survival effect of bariatric surgery [13,14]. However, we could not demonstrate a favorable survival effect of bariatric surgery in Korean obese patients because the observation period was limited to 18 months after surgery. Nevertheless, the weight reduction pattern we observed was comparable to those reported in previous studies, including the early (18-month) results of the Swedish Obese Subjects (SOS) study [13], a large-scale multicenter cohort study. In contrast, the control group in our study showed 8% weight loss after 18 months, whereas the control group in the SOS study showed only 1% weight change. The reasons for this discrepancy may be that the mean BMI of the control group was lower in the present study than in the SOS study, and that conventional medical therapy in the present study was actively conducted in tertiary hospitals.

Recovery from comorbidities such as diabetes, hypertension, and dyslipidemia was better in the surgery group than in the conventional therapy group in the present study. The remission of diabetes was observed in 57.1% of subjects in the surgery group and 9.5% of subjects in the conventional therapy group. This result was consistent with those of previous studies [15-17].

Buchwald et al. [17] reported a large-scale meta-analysis of 22,094 patients. In that study, diabetes was completely resolved in 76.8% of patients. In two comparative cohort studies, the SOS study [13] and the Utah Obesity study [14], diabetes remission rates were 66% and 74%, respectively, in the surgery groups, but <1% in the control groups.

Two prospective randomized trials assessing the results of surgical treatment of obese patients with diabetes have been published in the New England Journal of Medicine. Schauer et al. [18] evaluated the efficacy of intensive medical therapy alone versus medical therapy plus LRYGB or LSG in 150 obese patients with uncontrolled type 2 diabetes. The target HbA1C concentration of 6.0% or less at 12 months was achieved in 12%, 42%, and 37% of patients in the medical therapy, LRYGB, and LSG groups, respectively. The remission rates, evaluated by achievement of the endpoint without the use of hypoglycemic agents, were 0%, 100%, and 37%, respectively. Mingrone et al. [19] assigned patients to undergo RYGB, biliopancreatic diversion, or standard medical therapy. After 2 years, complete remission rates of diabetes were 75% for patients who underwent RYGB and 95% for those who underwent biliopancreatic diversion, whereas no remission occurred in the medical therapy group. In contrast, diabetes remission was also observed in the conventional therapy group in the present study because these patients received intensive medical treatment at a tertiary medical center.

Obesity remains a major cause of illness and death, and bariatric surgery appears to be the only intervention that consistently results in substantial, sustained weight loss. The surgical safety of bariatric surgery is an important consideration; many physicians and the general population in Korea appreciate that bariatric surgery is a risky procedure. In our study, the postoperative mortality rate was 0.38% (one case) and the immediate postoperative complication rate was 10%. The mortality rate in our study was comparable with that of a previous report in which the 30-day death rate among patients who underwent RYGB or LAGB was 0.3% [20]. However, the reported frequencies of adverse outcomes have varied and a direct comparison was not possible. In our study, the early postoperative complication rate of 10% and the rate of 13% after 30 days were considered to be acceptable because they included minor wound complications in the early period and long-term band-related complications in the late period.

This study had several limitations. First, although about 70% of bariatric surgeries in Korea are LAGBs performed in private clinics, this study included only those performed in tertiary hospitals. However, weight loss outcomes
did not differ among surgical groups. Thus, although we did not include data from private clinics, the results seem to be generalizable. Second, our study was not randomized or prospective, but was designed as a retrospective cohort study. Thus, baseline characteristics differed between groups. The surgery group was younger, female dominant, higher BMI, and more comorbidities. This is because younger female patient usually want to receive surgery, and surgeons recommend bariatric surgery for patients who have higher BMI and comorbidities. To overcome this limitation, we used various statistical methods such as matching and the GEE model to balance confounding factors at baseline between the two groups. The results of these analyses were robust. Third, long-term outcomes and complications could not be examined because of the short follow-up period.

In conclusion, bariatric surgery had a significant effect on weight loss when compared with conventional medical therapy in severely obese Korean patients. The recovery from comorbidities such as diabetes, hypertension, and dyslipidemia was better in the surgery group than in the conventional therapy group. Our results suggest that bariatric surgery may be a favorable option for treating severe obesity in Koreans. Further studies are needed to elucidate the weight loss mechanisms of bariatric surgery, improvement in comorbid diseases, and long-term outcomes of bariatric surgeries in Korea.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This study was completed as part of the health technology assessment report (project no. NA2011-003) funded by the National Evidence-based Healthcare Collaborating Agency (NECA) in Korea.

REFERENCES

1. Freedman DS; Centers for Disease Control and Prevention (CDC). Obesity: United States, 1988-2008. MMWR Surveill Summ 2011;60 Suppl:73-7.
2. Korea Centers for Disease Control and Prevention. Progress report on the national health and nutrition survey 2009 (health examination). Cheongwong: Korea Centers for Disease Control and Prevention; 2010.
3. Ramachandran A, Snehalatha C, Viswanathan V, Viswanathan M, Haffner SM. Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract 1997;36:121-5.
4. Wen CP, David Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr 2009;12:497-506.
5. Misra A. Redefining obesity in Asians: more definitive action is required from the WHO. Natl Med J India 2004;17:1-4.
6. Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. Ann Acad Med Singapore 2009;38:66-9.
7. Lee WJ, Wang W. Bariatric surgery: Asia-Pacific perspective. Obes Surg 2005;15:751-7.
8. Han SM, Kim WW. The 3-year results of laparoscopic sleeve gastrectomy for the treatment of Korean morbid obesity. J Korean Surg Soc 2007;73:400-5.
9. 1983 metropolitan height and weight tables. Stat Bull Metrop Life Found 1983;64:3-9.
10. Hanley JA, Negassa A, Edwards MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003;157:364-75.
11. Buddeberg-Fischer B, Klaghofer R, Krug L, Buddeberg C, Muller MK, Schoeb O, et al. Physical and psychosocial outcome in morbidly obese patients with and without bariatric surgery: a 4 1/2-year follow-up. Obes Surg 2006;16:321-30.
12. Dixon JB, Strauss BJ, Laurie C, O’Brien PE. Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs. Obesity (Silver Spring) 2007;15:1187-98.
13. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
14. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:733-61.
15. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-358.
16. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for
obesity. Cochrane Database Syst Rev 2009;(2):CD003641.

17. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.

18. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-76.

19. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-85.

20. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, King WC, Wahed AS, Berk P, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361:445-54.